Jasplatin 50 Injection contains Cisplatin 50 mg per 50 mL and is a platinum-based chemotherapeutic agent indicated for the treatment of various malignancies, including testicular, ovarian, bladder, lung, and head and neck cancers. Cisplatin exerts its antineoplastic effects by forming DNA crosslinks, thereby inhibiting DNA synthesis and function, leading to apoptosis of rapidly dividing cancer cells. Administered intravenously, Jasplatin 50 requires careful dosing and hydration protocols to minimize nephrotoxicity, a primary dose-limiting toxicity. Patients should be monitored for renal function, electrolyte imbalances, ototoxicity, neurotoxicity, and myelosuppression during therapy. Premedication with antiemetics is recommended to manage nausea and vomiting commonly associated with cisplatin administration. Dosage adjustments may be necessary in patients with impaired renal function or other comorbidities. Jasplatin 50 Injection should be used under strict oncological supervision with appropriate supportive care measures. Contraindications include hypersensitivity to cisplatin or other platinum compounds and pre-existing severe renal impairment. Proper handling and administration techniques must be observed to avoid extravasation and local tissue damage. This formulation is intended for intravenous infusion only and should not be administered by other routes. Careful patient selection and monitoring optimize therapeutic outcomes while minimizing adverse effects.